Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program

share with twitter share with LinkedIn share with facebook
share via e-mail
02/20/2020 | 05:15am EDT

By Carlo Martuscelli

 

Clinical-stage biotechnology business Immatics said Thursday that GlaxoSmithKline will license two of its T-cell therapy candidates being developed to treat cancer for a $50 million upfront payment.

Under the terms of the agreement, Glaxo will be responsible for developing, manufacturing and commercializing the investigative treatments. Immatics said that, in addition to the award upfront, is eligible for over $550 million in development, regulatory and commercial payments for each product, plus royalties.

The collaboration deal also includes the option for the British pharmaceutical company to license additional candidates. German biotech startup Immatics said that it is developing treatments that uses natural or engineered T-cells, a kind of immune cell, to fight solid tumors.

This latest deal brings Glaxo's cell-therapy pipeline up to six assets, from four previously. In Europe there are currently two approved cell-therapy products, both to treat certain blood cancers, developed by drug makers Gilead Science and Novartis.

 

Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu

 

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 1.60% 78.21 Delayed Quote.20.36%
GLAXOSMITHKLINE -0.25% 1489.4 Delayed Quote.-16.28%
NOVARTIS 1.08% 81.65 Delayed Quote.-12.10%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GLAXOSMITHKLINE
04/01Unilever PLC Completion of Horlicks acquisition from GSK
DJ
03/25Annual General Meeting Postponed of GlaxoSmithKline Consumer Healthcare Pakis..
AQ
03/23GLAXOSMITHKLINE : ViiV Healthcare announces first global regulatory approval of ..
AQ
03/23GLAXOSMITHKLINE : GSK appoints Charles Bancroft to the Board as a Non-Executive ..
AQ
03/20GLAXOSMITHKLINE : Description Report of Foreign Issuer
PU
03/18GLAXOSMITHKLINE : Description Report of Foreign Issuer
PU
03/17Change in date of Annual General Meeting of GlaxoSmithKline Consumer Healthca..
AQ
03/16Material Information of GlaxoSmithKline Consumer Healthcare Pakistan Limited
AQ
03/16GLAXOSMITHKLINE : Seventh Circuit Finds Albrecht Did Not Create A New Rule Of Pr..
AQ
03/16ZAI LAB : Says China Supplemental New Drug Application for Zejula Accepted
DJ
More news
Financials (GBP)
Sales 2020 34 835 M
EBIT 2020 9 009 M
Net income 2020 4 417 M
Debt 2020 23 339 M
Yield 2020 5,36%
P/E ratio 2020 17,5x
P/E ratio 2021 16,9x
EV / Sales2020 2,80x
EV / Sales2021 2,68x
Capitalization 74 319 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 1 825,09  GBp
Last Close Price 1 493,20  GBp
Spread / Highest target 50,0%
Spread / Average Target 22,2%
Spread / Lowest Target -2,89%
EPS Revisions
Managers
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-16.28%93 854
JOHNSON & JOHNSON-8.72%345 705
ROCHE HOLDING AG2.77%277 060
MERCK & CO., INC-16.16%195 141
NOVARTIS-12.10%187 703
PFIZER, INC.-14.14%181 075